Integrated solution combines Revolution Plus Sample Prep System with Hamilton Microlab STAR platform for cfDNA, cfRNA, cfTNA, and CTC extraction.
nRichDX and Hamilton announced progress on their strategic collaboration to deliver automated liquid biopsy sample preparation solutions, combining the nRichDX Revolution Plus Sample Prep System with the Hamilton Microlab STAR liquid handling platform.
The integrated solution enables automated, end-to-end workflows for isolating circulating cell-free DNA (cfDNA), circulating cell-free RNA (cfRNA), circulating cell-free total nucleic acid (cfTNA), and circulating tumor cells (CTCs) from plasma, urine, and other biofluids. The system accommodates sample input volumes ranging from 1 mL to 100 mL in a single extraction.
“nRichDX is setting a new standard for liquid biopsy sample preparation performance and workflow efficiency,” says William Curtis, CEO of nRichDX, in a release. “Together with Hamilton, we’re enabling laboratories to achieve the highest analyte yields while benefiting from flexible, scalable automation.”
Scalable Automation for Rare-Analyte Extraction
The collaboration, unveiled at the Association for Molecular Pathology Annual Meeting & Expo 2025, provides laboratories with walk-away automation for sensitive rare-analyte extraction. The solution aims to address yield limitations and workflow variability in liquid biopsy sample preparation.
The integrated platform delivers higher analyte yields, improved workflow efficiency and reproducibility, and flexibility in sample processing volumes. By eliminating yield-reducing steps such as pre-concentration, pooling, and re-elution, the system maximizes analyte recovery from blood, plasma, urine, and other biofluids.
“Our collaboration with nRichDX reflects Hamilton’s commitment to advancing precision medicine through robust, validated automation,” says Michael Mouradian, vice president of scientific strategy & market development at Hamilton, in a release. “By integrating the Revolution Plus System with the Hamilton Microlab STAR platform, we are enabling laboratories to achieve reproducible, high-performance liquid biopsy workflows that flexibly scale with both research and clinical demands.”
Clinical and Research Applications
At AMP 2025, the collaboration featured scientific presentations and multiple posters highlighting automated liquid biopsy workflows. The solution attracted interest from molecular diagnostics, translational research, and clinical laboratory professionals seeking to overcome challenges in rare-analyte extraction.
The companies report that joint development, customer pilots, and expanded commercial activity are currently underway based on engagement from the conference.
nRichDX’s Revolution Sample Prep System is designed as an IVD-labeled platform that processes volumes from 1 mL to 100 mL in a single extraction using the company’s nRicher Cartridges. Hamilton’s Microlab STAR platform provides precision liquid handling and laboratory automation capabilities.
Both companies are continuing to develop the integrated solution for research and clinical laboratory applications in liquid biopsy sample preparation.
Photo caption: The nRichDX Revolution Sample Prep Plus Processor for liquid biopsy (left) shown with the Hamilton Microlab STAR liquid handling platform (right).
Photo credit: nRichDX and Hamilton
